Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Glioblastoma 115Gliosarcoma 53Brain Neoplasms 53Glioma 47Central Nervous System Neoplasms 30Astrocytoma 29Melanoma 26Oligodendroglioma 14Neuroblastoma 10Neoplasm Metastasis 9Recurrence 7Ependymoma 7Sarcoma 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Skin Neoplasms 5Sarcoma, Ewing 5Lymphoma 5Breast Neoplasms 5Spinal Cord Neoplasms 4Somatostatinoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Lung Neoplasms 3Gastrinoma 3Carcinoma, Islet Cell 3Uveal Melanoma 2Rhabdomyosarcoma 2

Interventions

Temozolomide 1Irinotecan 1FANG vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Connective and Soft Tissue × Temozolomide × Clear all
NCT03495921 2023-04-26

VITA

Gradalis, Inc.

Phase 3 Terminated
32 enrolled 13 charts
Sarcoma

Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective Tissue, Sarcoma, Sarcoma, Ewing, Neoplasms, Connective and Soft Tissue, Neoplasms, Bone Tissue, Neuroectodermal Tumors, Primitive, Peripheral, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡